Cours InMed Pharmaceuticals Inc Canadian Securities Exchange
Actions
IN
CA4576371062
Recherche biotechnologique et médicale
CA 2024 * | 7,3 M 5,33 M 4,82 M | CA 2025 * | 9,12 M 6,66 M 6,03 M | Capitalisation | 2,01 M 1,46 M 1,33 M |
---|---|---|---|---|---|
Résultat net 2024 * | - | Résultat net 2025 * | - | VE / CA 2024 * | 0,27 x |
Trésorerie nette 2024 * | - 0 0 | Trésorerie nette 2025 * | - 0 0 | VE / CA 2025 * | 0,22 x |
PER 2024 * |
-
| PER 2025 * |
-
| Employés | - |
Rendement 2024 * |
-
| Rendement 2025 * |
-
| Flottant | 98,64% |
Dernier transcript sur InMed Pharmaceuticals Inc
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Eric Adams
CEO | Chief Executive Officer | 61 | 16/06/16 |
Chief Operating Officer | - | 05/11/18 | |
Colin Clancy
IRC | Investor Relations Contact | - | - |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Janet Grove
BRD | Director/Board Member | 57 | 11/02/22 |
Eric Adams
CEO | Chief Executive Officer | 61 | 16/06/16 |
Andrew Hull
CHM | Chairman | 61 | 12/09/16 |
Varia. 1 janv. | Capi. | |
---|---|---|
+8,96% | 105 Md | |
-1,43% | 104 Md | |
+4,40% | 22,94 Md | |
-12,15% | 22,34 Md | |
-4,36% | 19,25 Md | |
-39,98% | 17,08 Md | |
-10,04% | 16,96 Md | |
+38,61% | 12,63 Md | |
+313,59% | 8,49 Md |